FDA Risk Management Plan: Four Levels, From Labeling To Restricted Access
Executive Summary
FDA is proposing four levels of risk management programs for prescription drugs and biologics in a "Risk Management Programs" draft 1concept paper released March 6
You may also be interested in...
FDA Evaluation Of Risk Management Plans And “Tools” Needed, PhRMA Says
FDA should undertake a review of all current and past risk management plans and "tools" to document their effectiveness, PhRMA says
FDA Evaluation Of Risk Management Plans And “Tools” Needed, PhRMA Says
FDA should undertake a review of all current and past risk management plans and "tools" to document their effectiveness, PhRMA says
FDA Moves Ahead With Adverse Event Data-Mining; “White Paper” Out Soon
An FDA-PhRMA working group is finalizing a "white paper" on data mining as a tool in postmarketing safety surveillance